Login / Signup

Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.

Yuan-Kai ShiQiqing CaiYu JiangGang HuangMinghong BiBaocheng WangYuhong ZhouGuowen WangHongyan YingZhiwei TaoQian GuoChao Gao
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Geptanolimab has clinically meaningful activity and a manageable safety profile in unresectable, recurrent, or metastatic ASPS.
Keyphrases
  • phase ii
  • squamous cell carcinoma
  • clinical trial
  • small cell lung cancer
  • locally advanced
  • open label
  • liver metastases
  • phase iii
  • randomized controlled trial
  • rectal cancer
  • radiation therapy
  • placebo controlled